Genmab A/S (GMAB) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $0.49
- Estimate
- $0.40
- Surprise
- +23.8%
- Score at report (before → after)
- 6.0 → 5.9/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Genmab A/S (GMAB) beat the $0.40 estimate with diluted EPS of $0.49 — a large 23.8% upside surprise. TrendMatrix's engine moved from Hold (6.0/10) to Sell at 5.9/10 after the report — the engine's score fell despite the beat.
Where TrendMatrix's rating stands now
TrendMatrix currently rates GMAB Sell at 5.4/10.
2 of the last 4 quarters beat the estimate; this quarter's +23.8% surprise compares with a +2.5% four-quarter average. Next scheduled report: 2026-11-05.
What supports the rating
- V7 quality resilience bonus: +0.2 (Q=7.8 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Analyst target reached - limited upside remaining
- Near 52-week high (4.7% away)
- Consecutive earnings misses (2)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $33.74
- Price target
- $33.79
- Stop
- $32.10
- Upside to target
- +0.1%
- Reward-to-risk
- 0.0:1
The stock trades at 27.1× trailing but 21.6× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.
GMAB at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $21.15B
- P/E (fwd)
- 21.6
- P/E (ttm)
- 27.1
- 52-week range
- $23.62–$35.43
- Off 52-week high
- 4.8%
- RSI (14)
- 56
- Volume vs avg
- 0.19×
- Score today
- 5.4/10